Portage Biotech EBIT

The latest EBIT for PRTG is $-7.4M as of March 2025. That compares with $-17M in the prior-year period — up 56.7% year over year. That is below the Energy sector average of $200B. Investors often review this figure alongside Portage Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, PRTG's EBIT moved from $-17M to $-7.4M — a 56.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Portage Biotech's operating scale or balance-sheet position.

Against Energy companies, PRTG currently prints $-7.4M for EBIT, while the sector average sits near $200B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Portage Biotech's growth, margins, and balance sheet.

A EBIT figure of $-7.4M for PRTG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Energy average is about $200B. Explore the charts below for those layers of context.

After noting PRTG's EBIT ($-7.4M), review year-over-year change from $-17M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.